Tuesday Sanofi Announced Riliprubart One-year Follow-Up From Phase 2 Study Showed Efficacy And Safety, And Rapid And Durable Reduction Of Key Biomarkers, Including Those Associated With Classical Complement Pathway And Nerve Cell Damage
Tuesday Sanofi Announced Riliprubart One-year Follow-Up From Phase 2 Study Showed Efficacy And Safety, And Rapid And Durable Reduction Of Key Biomarkers, Including Those Associated With Classical Complement Pathway And Nerve Cell Damage
週二，賽諾菲安萬特公佈了Riliprubart 2期研究一年隨訪結果，顯示其具有良好的療效和安全性，能夠快速並持久地減少與經典補體途徑和神經元損傷相關的關鍵生物標誌物。
Tuesday Sanofi Announced Riliprubart One-year Follow-Up From Phase 2 Study Showed Efficacy And Safety, And Rapid And Durable Reduction Of Key Biomarkers, Including Those Associated With Classical Complement Pathway And Nerve Cell Damage
週二，賽諾菲安萬特公佈了Riliprubart 2期研究一年隨訪結果，顯示其具有良好的療效和安全性，能夠快速並持久地減少與經典補體途徑和神經元損傷相關的關鍵生物標誌物。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。